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This special section of this issue of the Artificial Intelligence in Medicine 
(AIIM) journal originates from the First Workshop on Artificial intelligence for 
Diabetes (AID 2016) on 30th August 2016. The workshop was part of the 22nd 
European Conference on Artificial Intelligence (ECAI 2016) in The Hague, 
Holland. Authors with papers accepted for the workshop were subsequently invited 
to revise and extend their work for publication in this issue, and a wider call was 
also announced to attract work from other outstanding researchers in the area. 
Following the success of the inaugural event, a Second Workshop  on Artificial 
intelligence for Diabetes (AID 2017) was held on 24th June 2017 under the 
umbrella of the Sixteenth European Conference on Artificial Intelligence in 
Medicine (AIME 2017) in Vienna Austria, and plans are already underway for    a 
third meeting. 
The complexities involved in the prognosis and management of diabetes has 
led to Artificial Intelligence (AI) becoming a key technology through which to 
provide solutions that empower both caregivers and patients in their everyday 
life. Several publicly-funded projects have been conducted to support diabetes 
management, such as: EMPOWER, MOBIGUIDE, COMMODITY12 EU, 
DIADVISOR, DIABEO, and the more recent PEPPER project. However, a lot of 
work remains to be done. The new series of international workshops on Artificial 
Intelligence in Diabetes (AID) from which this volume stems has therefore been 
established as a first step towards finding compatible and complementary tools 
for people with diabetes and building a research community in this important 
field. 
Authors were invited to submit original contributions on the overarching 
theme of Artificial Intelligence-based solutions to problems associated with 
diabetes. In particular, papers were sought on topics including Intelligent 
solutions to empower citizens with self-management of health conditions; 
Intelligent systems for glucose prediction and alarm generation; clinical decision 
support tools to deal with the avalanche of data gathered by sensors; data mining 
approaches for risk prediction and prevention of diabetes comorbidities; as well 
as community tools, platforms to support research in this area and data sets for 
benchmarking. 
Ten papers were received, and three papers have been accepted for 
publication in this special section, representing a small sample of the latest work 
in the area by several research groups. The papers are substantial extensions of 
the original ECAI 2016 workshop papers. 
The first paper, by Brown et al. [1], concerns decision support for patients. 
The focus is insulin-treated diabetes, which is predominantly type 1. The paper 
explores the use of case-based reasoning to personalise the insulin dose 
calculation in order to adapt to the specific circumstances of an individual. The 
novel aspect of the research is the use of temporal sequences to take into account 
preceding events, instead of considering events in isolation. The method shows 
promising in-silico results including a convincing reduction in the blood glucose 
risk index. 
The paper by López et al. [2] use the Random Forest technique to make 
predictions of risk to inform a decision support tool for clinicians. In this case 
the sphere of interest is the prognosis of type 2 diabetes. The aim of the work is 
to help clinicians to determine which Single Nucleotide Polymorphisms promote 
the development of the disease. Random Forests are used to seek the most 
significant attributes and assign weights according to risk contribution. The 
technique is shown to outperform both support vector machines and logistic 
regression in terms of prediction accuracy, as well as stability of the attribute 
weighting. 
The third paper by Saleh et al. [3]  explores the use of classifiers to determine 
the risk to each individual of developing diabetic retinopathy,  one of the most 
common long-term complications of diabetes. The   study uses two kinds of 
ensemble classifier: Fuzzy Random Forest and Dominance-Based Rough Set 
Balanced Rule Ensemble. The ultimate purpose of the work is to develop a 
personalised decision support system to 
 help clinicians to target scarce resources towards the patients who have the greatest need. 
 
We hope that readers will find the section stimulating to read. Although not fully 
comprehensive, the papers represent some current research trends at the forefront of interest 
to the Artificial Intelligence in Diabetes community. We would like to thank the contributing 
authors and also the reviewers who played an invaluable role in helping us compile this 
special issue: Chang Young Hwan, Robert Marti, Cindy Marling, Altoff Klaus Dieter, Isabelle 
Bichindaritz, Pau Herrero, Josep Lluis Arcos, Annette ten Teije, Nick Oliver, Eva Armengol, 
Ozgur Kafali, Suresh Munuswamy, Jenny Lundberg, Jorge Bondia, Marcelo Ledeira, Tjeerd 
olde Scheper, Peter Pesl and Benjamin Evans. 
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